Latest news with #Cumulus
Cision Canada
28-07-2025
- Health
- Cision Canada
Cumulus Neuroscience Presents Data at AAIC 2025 Annual Meeting and Technology and Dementia Preconference
Analysis of first-in-class CNS-101 study validates that at-home endpoints showed greater separation with Alzheimer's pathology (pTau217) than the benchmark endpoint Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13) over the study time-course BELFAST, Northern Ireland, July 28, 2025 /CNW/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, presented data from their real-world observational study CNS-101 at the Alzheimer's Association International Conference 2025 in Toronto, Ontario, Canada. Using the proprietary NeuLogiq ® Platform to gather data via repeated at-home sampling, the study was conducted in collaboration with the University of Cambridge. Cumulus presented a poster titled, "Frequent at-home multimodal measurements are more sensitive to progression than the gold-standard clinic-based ADAS-Cog composite scale" which featured data confirming repeated home-based digital cognitive endpoints are more sensitive to disease progression than the ADAS-Cog 13 composite benchmark, the primary cognitive scale used in Alzheimer's clinical trials today to determine drug efficacy. Additionally, passive electroencephalography (EEG) markers and naturalistic language-based markers collected with the NeuLogiq Platform are similarly powerful at detecting dementia progression as the ADAS-Cog 13, which requires a trained clinician and takes ~45 minutes to administer. "Clinic-based endpoints reflect snapshots in time, which limits the ability to track true disease progression and therapeutic efficacy in clinical research. Additionally, these endpoints lack sensitivity, objectivity, and are not scalable," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Our CNS-101 study was executed in collaboration with the Cumulus Pharma Advisory Group, which is comprised of leading scientists from ten top pharma companies. This first-in-class study has validated that patients living with Alzheimer's dementia are capable and willing to participate in clinical studies that include at-home longitudinal measures. Our NeuLogiq platform, which includes an award-winning FDA-cleared EEG headset, is user-friendly and suitable for repeated at-home use. We now have evidence that repeated real-world measurements at home provide higher statistical power than ADAS-Cog and could enable leaner study designs. We are deeply grateful to all the study participants and research collaborators." Additional analysis demonstrated that individual digital endpoints can enable streamlined study designs which may reduce overall costs, accelerating results leading to earlier go/no go decisions. In collaboration with the Cumulus Pharma Advisory Group, Cumulus will validate whether a digital composite measure may provide additional study power. "It's promising to see the increased sensitivity and statistical power of digital biomarkers from the wealth of data collected both at home and in the clinic in CNS-101," said Dr. Emer MacSweeney, Co-Founder & CEO of Re:Cognition Health's Brain and Mind Clinics which served as a leading CNS-101 clinical site. "The burden on study participants and patients is an important consideration when designing a clinical study in Alzheimer's Disease. Studies like CNS-101 are important to show the validity and sensitivity of digital biomarkers in developing CNS therapies and reducing the impact on patients and clinicians alike." Alzheimer's is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, difficulty with language and communication, mood swings, and changes in behavior and personality. While there is no known cure, there are currently over one hundred Alzheimer's disease clinical trials underway. In the CNS-101 Study, patients with dementia (N=59, ACE-III scores >60 and ≤88) and a matched cohort of healthy controls (N=60) were recruited across 7 sites in the UK including Cambridge and Oxford Universities and Re:Cognition Health's Brain and Mind Clinics in Plymouth and Guildford, for a 12-month repeated sampling study. Plasma samples were collected to confirm disease pathology. Participants were asked to complete repeated home-based sessions using the platform during the day, and to wear a sleep EEG device at night. Day sessions with a duration of approximately 30 minutes included 8 behavioral assessments on a mobile tablet (memory, executive function, affective processing and language) while synchronized EEG was recorded using the Cumulus 16-lead EEG headset. A staggered longitudinal protocol followed with burst sampling tapering to periodic sampling over the year. Benchmark paper-based assessments (including ADAS-Cog) and self-reported usability were collected at months 0, 6, and 12. Blood plasma was collected at months 6 and 12 for later biomarker analysis. Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit About Cumulus Neuroscience With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq ®, an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world's leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer's Disease, depression and schizophrenia. Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient's home – all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world's largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
Belfast Telegraph
08-07-2025
- Business
- Belfast Telegraph
Belfast health tech firm reveals expansion plans after securing £3.25m in funding
Cumulus aims to advance neuroscience clinical trials and patient care for conditions like Alzheimer's through improved data and AI, including the use of a headset. The round was led by a £1.5m investment from Whiterock's Growth Capital Fund, along with £1.25m from the Investment Fund for Northern Ireland's equity fund, £0.3m from Angel CoFund and £0.2m from Co Fund NI. Cumulus's NeuLogiq Platform helps biopharma partners and collaborators to advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. It uses a headset and tablet-based assessments to measure brain function across areas like cognition, mood, and language. It enables data to be collected more easily, including while patients are at home, which it said was useful for disorders such as Alzheimer's, where clinical testing can be difficult. Cumulus is headquartered in Belfast at Catalyst in the Titanic Quarter, where most of its 31 employees are based, with a second location in Dublin. The firm said the funding will be used to invest in marketing and recruit key staff such as a head of business to business marketing and sales operations, and a vice president of business development. Chief executive Tina Sampath said many clinical neuroscience studies were measured in pen and paper assessments which lacked objected data about brain function. 'Biopharma companies need objective data to effectively establish baseline information about whether a drug is engaging with the region of the brain that a particular drug is targeting, whether a drug is effective, and informing which cohort of patients may benefit the most from a particular drug.' She said Cumulus was well-placed to capitalise on opportunities in neuroscience clinical research. Whiterock's Growth Capital Fund makes investments of between £1m and £5m for minority shareholdings in growth and scaling companies in Northern Ireland. David McCurley, investment director at Whiterock, said: 'We are excited to have led this investment round to help fuel the next phase of growth for Cumulus with an equity investment from Whiterock's Growth Capital Fund. 'We look forward to partnering with Tina and the executive team as they deploy their groundbreaking technology and data analytics tools into projects alongside some of the world's leading pharma and biotech companies'. The £70m Investment Fund for Northern Ireland (IFNI) was launched by The British Business Bank to offer commercial finance including debt finance and equity investment. The equity fund is run by Clarendon Fund Managers. Whiterock also manages the debt fund, offering loans of £25,000 up to £2m, while Clarendon Fund Managers provide equity stakes in smaller businesses up to £5m. Brian Cummings, investment director at Clarendon Fund Managers, said: 'Clarendon is proud to continue our support of Cumulus Neuroscience through the IFNI Fund. 'The company's world-class technology holds immense potential to transform how neurological and psychiatric conditions are understood, monitored, and treated. In particular, Cumulus' work promises to revolutionise the diagnosis and treatment of diseases such as Alzheimer's, Parkinson's, and depression - conditions of growing global significance as the population ages.'
The Hindu
03-06-2025
- Entertainment
- The Hindu
Museum of Art & Photography installations to be exhibited at KIA Bengaluru
The Kempegowda International Airport (KIA) has partnered with the Museum of Art & Photography (MAP), Bengaluru to offer passengers a unique cultural experience in its Terminal 2 (T2). The Bangalore International Airport Limited (BIAL) which operates KIA, stated that this collaboration aims to transform the airport into a dynamic cultural hub, allowing travellers to engage with the rich tapestry of South Asian art and heritage during their journeys. Through thoughtfully curated interactive installations, featuring the works of celebrated artists, passengers will have the opportunity to explore and connect with the region's diverse creative legacy. T2 is already home to a collection of 210 carefully curated artworks by more than 60 artists. What can passengers explore? At T2's domestic terminal, passengers can enjoy a suite of immersive digital experiences curated by MAP which include: Gallery on Demand – Step into a world of artistic exploration with a rich digital library featuring works by renowned artists such as Jamini Roy, Jangarh Singh Shyam, Jyoti Bhatt, Suresh Punjabi, and L.N. Tallur. The platform also brings MAP's extensive film ephemera collection to life through curated stories built around Bollywood posters, stills, and lobby cards. From tracing the evolution of the tawaif figure to embarking on a journey through Arabian Nights, these narratives captivate and inform. A series of short films further offers intimate insights into the lives and practices of selected artists from the MAP collection. Interactive Puzzles – Engage with iconic artworks like Universe by S.H. Raza, Last Supper by Jamini Roy, and The Lotus Sellers by N.S. Bendre through touch-based puzzles that make art both playful and thought-provoking. Digital Lamp Lighting – Rooted in Indian tradition, lighting a lamp marks the beginning of something auspicious. This interactive feature lets travellers digitally light a lamp from MAP's collection by scanning a QR code and personalising the moment with their name — a small but meaningful pause in the journey. Cumulus – Digital Collection Viewing System – Dive deep into MAP's digitised archive using Cumulus, an intuitive application that lets users search, zoom, curate, and share artefacts. With tools for closer inspection and personal collection building, it's an ideal gateway for both casual discovery and deeper research. Virtual Greetings – Send animated digital festival and occasion-based greetings inspired by artworks in MAP's collection. Travellers can also explore an exclusive retail zone featuring MAP collection-inspired home and lifestyle products — ideal for souvenirs, gifts, or a personal piece of art to take home. T2's international terminal will host an exhibition 'Bhuri Bai: My Life as an Artist', spotlighting the journey of Padma Shri awardee Bhuri Bai. Hari Marar, MD & CEO, Bangalore International Airport Limited (BIAL), said, 'At KIA, we're reimagining what it means to travel — not just as a journey from one place to another, but as an experience enriched by culture, creativity, and connection. Our collaboration with MAP is a step in realising that vision, aiming to transform Terminal 2 into a vibrant hub of discovery and engagement. By bringing art into the passenger journey in such an accessible and interactive way, we hope to offer travellers moments of pause, inspiration, and reflection. It's our way of weaving the cultural richness of the region into the overall airport experience.'
Associated Press
04-04-2025
- Business
- Associated Press
Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting
Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer's pTau217 pathology than the benchmark Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) BELFAST, Northern Ireland, April 4, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, presented NeuLogiq® Platform validation data for two novel assessments of cognitive impairment in Alzheimer's dementia (AD), and proof-of-concept data in amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) at the AD/PD™ 2025 in Vienna, Austria. 'We are excited to share data validating NeuLogiq Platform cognitive tasks to measure memory, executive function and psychomotor function in broader neurodegenerative indications. We also demonstrated sensitivity to underlying Alzheimer's pathology, correlating to plasma ptau217 status,' said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. 'Additionally, our CNS-101 study demonstrated that patients could achieve high levels of adherence performing repeated cognitive and EEG tests at home to capture high quality data, making them suitable for use in clinical trials where precise measurement at the individual level is critical. Separately, data presented from our CNS-102 study provides proof-of-concept that NeuLogiq can capture data relevant in ALS-FTD, including patients with profound motor impairments. Collectively, these data confirm that the NeuLogiq Platform has the potential to enable earlier detection of disease and provide biopharma with longitudinal real-world data that can streamline clinical studies.' The first poster, titled 'Neuropsychological phenotyping of Alzheimer's dementia at home, using the Cumulus NeuLogiq Platform with plasma biomarkers,' featured data demonstrating that patients are willing and able to perform repeated cognitive and EEG testing at home, and the NeuLogiq Platform endpoints show greater separation with AD pathology (pTau217) than the benchmark endpoint (ADAS-Cog) throughout the study. Importantly, these endpoints accord with standard benchmarks and demonstrate patterns of patient impairment consistent with the literature. EEG biomarkers, including passive and task-based measures, demonstrate morphology and group differences as expected based on the literature. The second poster titled, 'Neurocognitive evaluation from the home: validation of the Cumulus Platform in FTD and ALS populations,' provided initial evidence that the NeuLogiq Platform can capture speech fluency and emotion recognition decline in patients living with ALS, offering potential utility as a digital biomarker of cognitive decline, in addition to providing proof-of-concept that the platform can capture meaningful neuropsychological data, relevant to the heterogeneity of the ALS-FTD phenotype. Cumulus continues to advance the NeuLogiq Platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit About Alzheimer's Disease and pTau217 Alzheimer's is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, mood swings, changes in behavior and personality, and difficulty with language and communication. Currently, there is no known cure for Alzheimer's. Today, earlier diagnosis can enable patients to make lifestyle changes, including exercising and decreasing alcohol consumption, both of which have been shown to slow disease progression. In the future, having the ability to diagnose patients earlier may expedite enrollment in clinical studies and the identification of new treatments. pTau217, a phosphorylated fragment of the tau protein, is a promising blood-based biomarker for detecting Alzheimer's disease (AD) pathology, showing high accuracy in identifying amyloid and tau pathology, and potentially distinguishing AD from other neurodegenerative disorders. About Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) ALS and FTD are two neurodegenerative diseases that share some similarities but also have distinct characteristics. ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to the loss of motor neuron function and eventually causing muscle weakness and paralysis. FTD involves the progressive degeneration of neurons in the areas of the brain behind the forehead (the frontal lobe) and behind the ears (the temporal lobes), leading to changes in personality, behavior, and language. About Cumulus Neuroscience Our mission is to generate the data and insights required to accelerate the diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world. At Cumulus Neuroscience, we are advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform designed with 10 of the world's leading pharma companies. This novel platform provides the critical data and insights needed for faster, more robust and cost-effective decision-making in clinical trials and patient care. NeuLogiq enables study sponsors to capture large amounts of real-world clinical data repeatedly over time, across multiple behavioral and physiological domains, in the clinic and at home. Together with machine learning (ML) analytics, Cumulus simplifies and improves the robustness of CNS clinical trials, providing objective assessment of study inclusion and treatment outcomes.
Yahoo
04-04-2025
- Business
- Yahoo
Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting
Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer's pTau217 pathology than the benchmark Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) BELFAST, Northern Ireland, April 4, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, presented NeuLogiq® Platform validation data for two novel assessments of cognitive impairment in Alzheimer's dementia (AD), and proof-of-concept data in amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) at the AD/PD™ 2025 in Vienna, Austria. "We are excited to share data validating NeuLogiq Platform cognitive tasks to measure memory, executive function and psychomotor function in broader neurodegenerative indications. We also demonstrated sensitivity to underlying Alzheimer's pathology, correlating to plasma ptau217 status," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Additionally, our CNS-101 study demonstrated that patients could achieve high levels of adherence performing repeated cognitive and EEG tests at home to capture high quality data, making them suitable for use in clinical trials where precise measurement at the individual level is critical. Separately, data presented from our CNS-102 study provides proof-of-concept that NeuLogiq can capture data relevant in ALS-FTD, including patients with profound motor impairments. Collectively, these data confirm that the NeuLogiq Platform has the potential to enable earlier detection of disease and provide biopharma with longitudinal real-world data that can streamline clinical studies." The first poster, titled "Neuropsychological phenotyping of Alzheimer's dementia at home, using the Cumulus NeuLogiq Platform with plasma biomarkers," featured data demonstrating that patients are willing and able to perform repeated cognitive and EEG testing at home, and the NeuLogiq Platform endpoints show greater separation with AD pathology (pTau217) than the benchmark endpoint (ADAS-Cog) throughout the study. Importantly, these endpoints accord with standard benchmarks and demonstrate patterns of patient impairment consistent with the literature. EEG biomarkers, including passive and task-based measures, demonstrate morphology and group differences as expected based on the literature. The second poster titled, "Neurocognitive evaluation from the home: validation of the Cumulus Platform in FTD and ALS populations," provided initial evidence that the NeuLogiq Platform can capture speech fluency and emotion recognition decline in patients living with ALS, offering potential utility as a digital biomarker of cognitive decline, in addition to providing proof-of-concept that the platform can capture meaningful neuropsychological data, relevant to the heterogeneity of the ALS-FTD phenotype. Cumulus continues to advance the NeuLogiq Platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit About Alzheimer's Disease and pTau217Alzheimer's is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, mood swings, changes in behavior and personality, and difficulty with language and communication. Currently, there is no known cure for Alzheimer's. Today, earlier diagnosis can enable patients to make lifestyle changes, including exercising and decreasing alcohol consumption, both of which have been shown to slow disease progression. In the future, having the ability to diagnose patients earlier may expedite enrollment in clinical studies and the identification of new treatments. pTau217, a phosphorylated fragment of the tau protein, is a promising blood-based biomarker for detecting Alzheimer's disease (AD) pathology, showing high accuracy in identifying amyloid and tau pathology, and potentially distinguishing AD from other neurodegenerative disorders. About Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) ALS and FTD are two neurodegenerative diseases that share some similarities but also have distinct characteristics. ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to the loss of motor neuron function and eventually causing muscle weakness and paralysis. FTD involves the progressive degeneration of neurons in the areas of the brain behind the forehead (the frontal lobe) and behind the ears (the temporal lobes), leading to changes in personality, behavior, and language. About Cumulus Neuroscience Our mission is to generate the data and insights required to accelerate the diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world. At Cumulus Neuroscience, we are advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform designed with 10 of the world's leading pharma companies. This novel platform provides the critical data and insights needed for faster, more robust and cost-effective decision-making in clinical trials and patient care. NeuLogiq enables study sponsors to capture large amounts of real-world clinical data repeatedly over time, across multiple behavioral and physiological domains, in the clinic and at home. Together with machine learning (ML) analytics, Cumulus simplifies and improves the robustness of CNS clinical trials, providing objective assessment of study inclusion and treatment outcomes. FOR MORE INFORMATIONTina Tel: 415.694.1175 Logo: View original content: Sign in to access your portfolio
